US Patent Issued to Paradigm Biopharmaceuticals on Oct. 7 for "Treatment of acute respiratory disease syndrome (ARDS) with polysulfated polysaccharides" (Australian Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,433,913, issued on Oct. 7, was assigned to Paradigm Biopharmaceuticals Ltd. (Melbourne, Australia).

"Treatment of acute respiratory disease syndrome (ARDS) with polysulfated polysaccharides" was invented by Paul Rennie (Melbourne, Australia) and Ravi Krishnan (Melbourne, Australia).

According to the abstract* released by the U.S. Patent & Trademark Office: "Methods for the treatment of Acute Respiratory Distress Syndrome (ARDS), particularly ARDS caused by viral infections such as influenza and SARS-CoV-2, comprising the administration of pentosan polysulfate (PPS) are provided. Some provided methods comprise the administration of sodium pentosan polysulfate. Prophylactic methods comp...